Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Overcoming evasive resistance from vascular endothelial growth factor a inhibition in sarcomas by genetic or pharmacologic targeting of hypoxia-inducible factor 1α.

Kim YJ, Lee HJ, Kim TM, Eisinger-Mathason TS, Zhang AY, Schmidt B, Karl DL, Nakazawa MS, Park PJ, Simon MC, Yoon SS.

Int J Cancer. 2013 Jan 1;132(1):29-41. doi: 10.1002/ijc.27666. Epub 2012 Jun 26.

2.

Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1α maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature.

Lee HJ, Yoon C, Park do J, Kim YJ, Schmidt B, Lee YJ, Tap WD, Eisinger-Mathason TS, Choy E, Kirsch DG, Simon MC, Yoon SS.

Int J Radiat Oncol Biol Phys. 2015 Mar 1;91(3):621-30. doi: 10.1016/j.ijrobp.2014.10.047. Epub 2014 Dec 24.

3.

Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A.

Detwiller KY, Fernando NT, Segal NH, Ryeom SW, D'Amore PA, Yoon SS.

Cancer Res. 2005 Jul 1;65(13):5881-9.

4.

Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells.

Duyndam MC, van Berkel MP, Dorsman JC, Rockx DA, Pinedo HM, Boven E.

Biochem Pharmacol. 2007 Jul 15;74(2):191-201. Epub 2007 Apr 6.

PMID:
17498666
5.

Expression patterns of the hypoxia-related genes osteopontin, CA9, erythropoietin, VEGF and HIF-1alpha in human glioma in vitro and in vivo.

Said HM, Hagemann C, Staab A, Stojic J, Kühnel S, Vince GH, Flentje M, Roosen K, Vordermark D.

Radiother Oncol. 2007 Jun;83(3):398-405. Epub 2007 May 23.

PMID:
17524506
6.

Se-methylselenocysteine sensitizes hypoxic tumor cells to irinotecan by targeting hypoxia-inducible factor 1alpha.

Chintala S, Tóth K, Cao S, Durrani FA, Vaughan MM, Jensen RL, Rustum YM.

Cancer Chemother Pharmacol. 2010 Oct;66(5):899-911. doi: 10.1007/s00280-009-1238-8. Epub 2010 Jan 12.

7.

Increased activation of the hypoxia-inducible factor pathway in varicose veins.

Lim CS, Kiriakidis S, Paleolog EM, Davies AH.

J Vasc Surg. 2012 May;55(5):1427-39. doi: 10.1016/j.jvs.2011.10.111. Epub 2012 Jan 24.

8.

Expression of vascular endothelial growth factor, hypoxia inducible factor 1alpha, and carbonic anhydrase IX in human tumours.

Jubb AM, Pham TQ, Hanby AM, Frantz GD, Peale FV, Wu TD, Koeppen HW, Hillan KJ.

J Clin Pathol. 2004 May;57(5):504-12.

9.

Hypoxia-inducible factor-1α mRNA: a new target for destabilization by tristetraprolin in endothelial cells.

Chamboredon S, Ciais D, Desroches-Castan A, Savi P, Bono F, Feige JJ, Cherradi N.

Mol Biol Cell. 2011 Sep;22(18):3366-78. doi: 10.1091/mbc.E10-07-0617. Epub 2011 Jul 20.

10.

Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.

Chen MC, Lee CF, Huang WH, Chou TC.

Biochem Pharmacol. 2013 May 1;85(9):1278-87. doi: 10.1016/j.bcp.2013.02.009. Epub 2013 Feb 14.

PMID:
23416116
11.

Fasudil-induced hypoxia-inducible factor-1alpha degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells.

Takata K, Morishige K, Takahashi T, Hashimoto K, Tsutsumi S, Yin L, Ohta T, Kawagoe J, Takahashi K, Kurachi H.

Mol Cancer Ther. 2008 Jun;7(6):1551-61. doi: 10.1158/1535-7163.MCT-07-0428.

13.

Is the hypoxia-inducible factor pathway important in gastric cancer?

Griffiths EA, Pritchard SA, Welch IM, Price PM, West CM.

Eur J Cancer. 2005 Dec;41(18):2792-805. Epub 2005 Nov 14. Review.

PMID:
16290133
14.

Activation of hypoxia-induced transcription in normoxia.

Hägg M, Wennström S.

Exp Cell Res. 2005 May 15;306(1):180-91. Epub 2005 Mar 19.

PMID:
15878343
15.

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.

Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH, Melillo G.

Mol Cancer Ther. 2009 Jul;8(7):1867-77. doi: 10.1158/1535-7163.MCT-09-0274. Epub 2009 Jul 7.

16.

Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.

Paradziej-Łukowicz J, Skwarska A, Peszyńska-Sularz G, Brillowska-Dąbrowska A, Konopa J.

Cancer Biol Ther. 2011 Oct 1;12(7):586-97. Epub 2011 Oct 1.

PMID:
21775820
17.

Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival.

Hui EP, Chan AT, Pezzella F, Turley H, To KF, Poon TC, Zee B, Mo F, Teo PM, Huang DP, Gatter KC, Johnson PJ, Harris AL.

Clin Cancer Res. 2002 Aug;8(8):2595-604.

19.

Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.

Patterson DM, Gao D, Trahan DN, Johnson BA, Ludwig A, Barbieri E, Chen Z, Diaz-Miron J, Vassilev L, Shohet JM, Kim ES.

Angiogenesis. 2011 Sep;14(3):255-66. doi: 10.1007/s10456-011-9210-8. Epub 2011 Apr 12.

PMID:
21484514
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk